184 related articles for article (PubMed ID: 15935663)
1. Pharmacophore-based design, synthesis, biological evaluation, and 3D-QSAR studies of aryl-piperazines as alpha(1)-adrenoceptor antagonists.
Li MY; Fang H; Xia L
Bioorg Med Chem Lett; 2005 Jul; 15(13):3216-9. PubMed ID: 15935663
[TBL] [Abstract][Full Text] [Related]
2. Rational design, synthesis, biologic evaluation, and structure-activity relationship studies of novel 1-indanone alpha(1)-adrenoceptor antagonists.
Li M; Xia L
Chem Biol Drug Des; 2007 Nov; 70(5):461-4. PubMed ID: 17927718
[TBL] [Abstract][Full Text] [Related]
3. N-arylpiperazinyl-N'-propylamino derivatives of heteroaryl amides as functional uroselective alpha 1-adrenoceptor antagonists.
Elworthy TR; Ford AP; Bantle GW; Morgans DJ; Ozer RS; Palmer WS; Repke DB; Romero M; Sandoval L; Sjogren EB; Talamás FX; Vazquez A; Wu H; Arredondo NF; Blue DR; DeSousa A; Gross LM; Kava MS; Lesnick JD; Vimont RL; Williams TJ; Zhu QM; Pfister JR; Clarke DE
J Med Chem; 1997 Aug; 40(17):2674-87. PubMed ID: 9276013
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of novel alpha1a adrenoceptor-selective dihydropyridine antagonists for the treatment of benign prostatic hyperplasia.
Nagarathnam D; Wetzel JM; Miao SW; Marzabadi MR; Chiu G; Wong WC; Hong X; Fang J; Forray C; Branchek TA; Heydorn WE; Chang RS; Broten T; Schorn TW; Gluchowski C
J Med Chem; 1998 Dec; 41(26):5320-33. PubMed ID: 9857099
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, alpha 1-adrenoceptor antagonist activity, and SAR study of novel arylpiperazine derivatives of phenytoin.
Handzlik J; Maciag D; Kubacka M; Mogilski S; Filipek B; Stadnicka K; Kieć-Kononowicz K
Bioorg Med Chem; 2008 Jun; 16(11):5982-98. PubMed ID: 18490167
[TBL] [Abstract][Full Text] [Related]
6. Alpha1-adrenoceptor antagonists. 6. Structural optimization of pyridazinone-arylpiperazines. Study of the influence on affinity and selectivity of cyclic substituents at the pyridazinone ring and alkoxy groups at the arylpiperazine moiety.
Betti L; Corelli F; Floridi M; Giannaccini G; Maccari L; Manetti F; Strappaghetti G; Botta M
J Med Chem; 2003 Jul; 46(16):3555-8. PubMed ID: 12877594
[TBL] [Abstract][Full Text] [Related]
7. 1-Arylpiperazinyl-4-cyclohexylamine derived isoindole-1,3-diones as potent and selective alpha-1a/1d adrenergic receptor ligands.
Li S; Chiu G; Pulito VL; Liu J; Connolly PJ; Middleton SA
Bioorg Med Chem Lett; 2007 Mar; 17(6):1646-50. PubMed ID: 17254786
[TBL] [Abstract][Full Text] [Related]
8. Quantitative structure-activity relationship study of novel alpha1a-selective adrenoceptor antagonists.
Singh P; Kumar R
J Enzyme Inhib; 2001 Oct; 16(4):331-8. PubMed ID: 11916138
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, pharmacological evaluation, and structure-activity relationship and quantitative structure-activity relationship studies on novel derivatives of 2,4-diamino-6,7-dimethoxyquinazoline alpha1-adrenoceptor antagonists.
Leonardi A; Motta G; Boi C; Testa R; Poggesi E; De Benedetti PG; Menziani MC
J Med Chem; 1999 Feb; 42(3):427-37. PubMed ID: 9986714
[TBL] [Abstract][Full Text] [Related]
10. (Arylpiperazinyl)cyclohexylsufonamides: discovery of alpha(1a/1d)-selective adrenergic receptor antagonists for the treatment of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms (BPH/LUTS).
Chiu G; Li S; Connolly PJ; Pulito V; Liu J; Middleton SA
Bioorg Med Chem Lett; 2007 Jun; 17(12):3292-7. PubMed ID: 17452102
[TBL] [Abstract][Full Text] [Related]
11. Aminocyclohexylsulfonamides: discovery of metabolically stable alpha(1a/1d)-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).
Chiu G; Li S; Cai H; Connolly PJ; Peng S; Stauber K; Pulito V; Liu J; Middleton SA
Bioorg Med Chem Lett; 2007 Nov; 17(22):6123-8. PubMed ID: 17904840
[TBL] [Abstract][Full Text] [Related]
12. Ligand-based pharmacophore model of N-Aryl and N-Heteroaryl piperazine alpha 1A-adrenoceptors antagonists using GALAHAD.
Zhao X; Yuan M; Huang B; Ji H; Zhu L
J Mol Graph Model; 2010 Sep; 29(2):126-36. PubMed ID: 20538497
[TBL] [Abstract][Full Text] [Related]
13. RBx 6198: a novel alpha1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia.
Nanda K; Naruganahalli KS; Gupta S; Malhotra S; Tiwari A; Hegde LG; Jain S; Sinha N; Gupta JB; Chugh A; Anand N; Ray A
Eur J Pharmacol; 2009 Apr; 607(1-3):213-9. PubMed ID: 19239913
[TBL] [Abstract][Full Text] [Related]
14. Prostate growth inhibition by subtype-selective alpha(1)-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia.
Kojima Y; Sasaki S; Oda N; Koshimizu TA; Hayashi Y; Kiniwa M; Tsujimoto G; Kohri K
Prostate; 2009 Oct; 69(14):1521-8. PubMed ID: 19544328
[TBL] [Abstract][Full Text] [Related]
15. (Phenylpiperidinyl)cyclohexylsulfonamides: development of alpha1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).
Chiu G; Li S; Connolly PJ; Pulito V; Liu J; Middleton SA
Bioorg Med Chem Lett; 2007 Jul; 17(14):3930-4. PubMed ID: 17517507
[TBL] [Abstract][Full Text] [Related]
16. Selective pharmacophore design for alpha1-adrenoceptor subtypes.
MacDougall IJ; Griffith R
J Mol Graph Model; 2006 Sep; 25(1):146-57. PubMed ID: 16406718
[TBL] [Abstract][Full Text] [Related]
17. Alpha(1) adrenoceptor subtype selectivity. 3D-QSAR models for a new class of alpha(1) adrenoceptor antagonists derived from the novel antipsychotic sertindole.
Balle T; Andersen K; Søby KK; Liljefors T
J Mol Graph Model; 2003 Jun; 21(6):523-34. PubMed ID: 12676239
[TBL] [Abstract][Full Text] [Related]
18. Change of expression levels of alpha1-adrenoceptor subtypes by administration of alpha1d-adrenoceptor-subtype-selective antagonist naftopidil in benign prostate hyperplasia patients.
Kojima Y; Sasaki S; Shinoura H; Hayase M; Kubota Y; Hayashi Y; Tsujimoto G; Kohri K
Prostate; 2007 Sep; 67(12):1285-92. PubMed ID: 17626248
[TBL] [Abstract][Full Text] [Related]
19. Rational design, synthesis, biological evaluation, homology and docking studies of coumarin derivatives as α1 -adrenoceptor antagonists.
Zhou X; Chen YD; Wang T; Wang XB; Kong LY
Chem Biodivers; 2011 Jun; 8(6):1052-64. PubMed ID: 21674779
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of prazosin-related derivatives as multipotent compounds.
Antonello A; Hrelia P; Leonardi A; Marucci G; Rosini M; Tarozzi A; Tumiatti V; Melchiorre C
J Med Chem; 2005 Jan; 48(1):28-31. PubMed ID: 15633998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
